|Application ||WB, IHC-P, E|
|Dilution||ELISA (1:1000), IHC-P (5 µg/ml), WB (1:500-1:1000)|
|Other Names||Neurotensin receptor type 1, NT-R-1, NTR1, High-affinity levocabastine-insensitive neurotensin receptor, NTRH, NTSR1, NTRR|
|Target/Specificity||NTR1 Antibody detects endogenous levels of total NTR1 protein.|
|Reconstitution & Storage||Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.|
|Precautions||NTSR1 / NTR Antibody (aa181-230) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||G-protein coupled receptor for the tridecapeptide neurotensin (NTS) (PubMed:8381365, PubMed:21725197, PubMed:23140271). Signaling is effected via G proteins that activate a phosphatidylinositol-calcium second messenger system. Signaling leads to the activation of downstream MAP kinases and protects cells against apoptosis (PubMed:21725197).|
|Cellular Location||Cell membrane; Multi-pass membrane protein. Membrane raft. Note=Palmitoylation is required for localization at CAV1-enriched membrane rafts|
|Tissue Location||Expressed in prostate (at protein level). Detected in colon and peripheral blood mononuclear cells. Detected at very low levels in brain.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
G-protein coupled receptor for the tridecapeptide neurotensin (NTS). Signaling is effected via G proteins that activate a phosphatidylinositol-calcium second messenger system. Signaling leads to the activation of downstream MAP kinases and protects cells against apoptosis.
Vita N.,et al.FEBS Lett. 317:139-142(1993).
Kopatz S.A.,et al.Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
Deloukas P.,et al.Nature 414:865-871(2001).
Swift S.L.,et al.Cancer Res. 70:347-356(2010).
Heakal Y.,et al.Cancer Biol. Ther. 12:427-435(2011).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.